Prodocs Solutions Ltd. IPO Allotment Status: Check Overall Subscription & Steps to Verify Status
The basis of allotment for Prodocs Solutions Ltd. IPO is expected to be finalised today, December 11, 2025. The IPO opened for subscription on December 8, 2025, and closed yesterday, December 10, 2025. It is a book build issue of ₹27.60 crores, which combines a fresh issue of 0.16 crore shares and an offer-for-sale (OFS) of 0.04 crore shares.
The tentative IPO listing date is December 15, 2025, and it will list on the BSE SME.
Check Prodocs Solutions Ltd. IPO Allotment Status on BSE and the registrar’s website.
Procedure to Check Prodocs Solutions Ltd. IPO Allotment Status Online On BSE
- Click here to visit the application status page.
- In Issue Type, “Equity”.
- In Issue Name, select “Prodocs Solutions Ltd”.
- Enter your “Application No.” or “PAN No.”
- Click on “I am not a robot”.
- Click “Submit”.
Procedure to Check Prodocs Solutions Ltd. IPO Allotment Status on MUFG Intime India Private Limited (Registrar to the issue)
- Click here to visit MUFG Intime’s application status page.
- Under, Please select company, select “Prodocs Solutions Ltd”.
- Enter any of the following details.
- PAN
- App. No.
- DP/Client ID
- Account No / IFSC
- Click “Submit”.
Prodocs Solutions Ltd. IPO Details
- The Prodocs Solutions Ltd. IPO is a book build issue of ₹27.60 crores, comprising a fresh issue of 0.16 crore shares aggregating to ₹22.08 crores and an OFS of 0.04 crore shares aggregating to ₹5.52 crores.
- The price band for the IPO has been set at ₹131.00 to ₹138.00 per share.
- The lot size for applications is 1,000.
- The minimum investment amount for individual/retail investors is ₹2,76,000.00 or 2,000 shares, based on the upper price. The minimum lot size for HNIs is 3 lots or 3,000 shares, aggregating to a cumulative amount of ₹4,14,000.
- The book running lead manager is Cumulative Capital Pvt. Ltd., and MUFG Intime India Pvt. Ltd. is the issue registrar. The Market Maker of the company is Fortune Fiscal Limited.
Prodocs Solutions Ltd. IPO Overall Subscription Status
When the Prodocs Solutions Ltd. IPO closed for subscription, it saw an overall subscription of 2.66 times as per the BSE data as of December 10, 2025, at the end of the day.
The public issue was subscribed:
- 2.38 times by Retail Individual Investors (RIIs)
- 4.61 times by Non-Institutional Investors (NIIs)
- 1.59 times by Qualified Institutional Buyers (QIBs)
Explore other Upcoming IPOs on BSE and NSE.
Utilisation of Proceeds
The company plans to utilise the net proceeds from the fresh issue towards:
- ₹4.31 crore for the design, development, implementation and support for a tailored software to meet the company’s specific needs.
- ₹3.93 crore for funding capital expenditure towards buying and installing IT equipment, computer hardware, and ancillary equipment.
- ₹3.77 crore for repayment or prepayment in full/part of specific outstanding borrowings.
- ₹4.50 crore for funding the company’s working capital requirements.
- General corporate purposes.
Check out newly Listed IPOs on BSE and NSE.
About Prodocs Solutions Ltd.
Founded in March 2019, Prodocs Solutions Ltd. is involved in ITeS/BPO, primarily in the non-voice BPO segment. It offers several services, including e-publishing, indexing, title services, finance and accounting, and litigation support. There are offshore solutions to meet client needs, mainly in the US and Australia. It has a workforce of 1,000+ based in Mumbai at its dedicated delivery facility.
Financially, the company reported:
- A revenue decrease of 6% and growth in PAT (profit after tax) of 61% between the financial year ending with March 31, 2025 and March 31, 2024
- ₹38.94 crore in assets and total income of ₹21.11 crore as of September 30, 2025
- EBITDA and net worth of ₹5.53 crore and ₹22.43 crore as of September 30, 2025
- Reserves and surplus of ₹16.98 crore by September 30, 2025, along with total borrowing of ₹7.46 crore by this date
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.